Barclays analyst Carter Gould raised the firm’s price target on Eli Lilly to $500 from $420 and keeps an Overweight rating on the shares. The company’s incretin pipeline “bests even high expectations,” emerging with reinforced leadership supported by best-in-class oral for orforglipron, landmark efficacy data on retatrutide, and competitor setbacks, the analyst tells investors in a research note. The firm raised its 2030 incretin portfolio estimates to $49B from $38B-$40B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LLY:
- Here’s 2023’s Best-Performing Actively-Managed ETF
- Eli Lilly (NYSE:LLY) Touts Superior Results of Weight Loss Shot
- Pfizer’s (NYSE:PFE) Oral Obesity Drug Plans Get Leaner
- Eli Lilly says Phase 2 retatrutide study met primary endpoint
- Cantor biotech/biopharma analysts hold analyst/industry conference call
